Dual–Dual Action? Combining Venlafaxine and Mirtazapine in the Treatment of Depression
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Objective: Venlafaxine and mirtazapine in combination are increasingly used in clinical practice to treat treatment-refractory depression. Putative efficacy for this combination of antidepressants, beyond that of monotherapy, stems from their synergistic actions. This paper describes a prospective case series that examined the efficacy of the venlafaxine–mirtazapine combination in the treatment of depressed patients who had failed at least one antidepressant trial. Method: Twenty-two depressed patients with major depression were treated with venlafaxine and mirtazapine in combination for an average of just under 8weeks. Baseline ratings on the 17-item Hamilton Depression Rating Scale (HAM-D 17), Montgomery–Åsberg Depression Rating Scale (MADRS) and the Clinical Global Impression–Severity Scale (CGI-S) were repeated at end-point, determined by the naturalistic termination of the depressive treatment episode or the discontinuation of the combination treatment due to adverse effects. The length of treatment until end-point was documented for each patient. Descriptive statistics were used on the collated data. Results: At baseline, mean scores were 28.8 (SD=3.8) for HAM-D 17, 30.1 (SD=5.8) for MADRS, and 4.5 (SD=0.5) for CGI-S, reflecting a cohort at the moderate to severe end of the spectrum. At end-point, mean absolute scores were 10.2 (SD=4.7) for HAM-D 17, 10.8 (SD=4.6) for MADRS, and 2.3 (SD=0.6) for CGI-S. Mean change from baseline was 18.6 (SD=6.4) for HAM-D 17, 19.3 (SD=6.8) for MADRS, and 2.3 (SD=0.6) for CGI-S. Mean duration of treatment was approximately 8weeks, producing a response rate of 81.8% and a remission rate of 27.3%. Only one patient was unable to tolerate the combination although nearly half (10) had significant side-effects during treatment. Conclusion: This study demonstrates relatively high response and remission rates that are encouraging and contribute to the efficacy database for this antidepressant combination. Further studies using randomized controlled designs are needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052963 · Cited by 1,033
Medication Augmentation after the Failure of SSRIs for Depression
Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A. A., Lebowitz, B. D., Biggs, M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052964 · Cited by 1,002
fMRI during affect discrimination in bipolar affective disorder
Yurgelun‐Todd, D. A., Gruber, S. A., Kanayama, G., Killgore, W. D., Baird, A. A., & Young, A. D. (2000) · Bipolar Disorders · doi:10.1034/j.1399-5618.2000.20304.x · Cited by 359
Cited by
Malhi, G. S., & Mann, J. J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31948-2 · Cited by 4,099
Self-citationMalhi, G. S., Bassett, D., Boyce, P., Bryant, R., Fitzgerald, P. B., Fritz, K., Hopwood, M., Lyndon, B., Mulder, R., Murray, G., et al. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867415617657 · Cited by 842
“For example, venlafaxine and mirtazapine are pharmacologically synergistic or complementary because of their distinct receptor profiles (Malhi et al., 2008).”
BackgroundSelf-citationTreatment-resistant depression: therapeutic trends, challenges, and future directions
Al-harbi (2012) · Patient Preference and Adherence · doi:10.2147/ppa.s29716 · Cited by 796
“However, lithium is known to have a narrow therapeutic window and needs blood level monitoring to avoid the toxicity and fatalities associated with high lithium levels.(77,78,80) With regard to newer generations of antidepressants, after failure of a first-line SSRI, neither a switch within a class nor a switch to a d…”
Epidemiology of treatment resistant depression among major depressive disorder patients in Israel
Sharman Moser, S., Chodick, G., Gelerstein, S., Barit Ben David, N., Shalev, V., & Stein-Reisner, O. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-04184-8 · Cited by 23
Kavanagh, B. E., Brennan-Olsen, S. L., Turner, A., Dean, O. M., Berk, M., Ashton, M. M., Koivumaa-Honkanen, H., & Williams, L. J. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-025145 · Cited by 9
Self-citation
Metadata
- Authors
- Malhi, G. S., Ng, F., & Berk, M.
- Venue
- Australian & New Zealand Journal of Psychiatry
- Publisher
- SAGE Publications
- Published
- 2008-01-01
- Volume
- 42
- Issue
- 4
- Pages
- 346-349
- ISSN
- 0004-8674 (ISSN-L)
- 1440-1614
- OpenAlex
- W2053261742
- Cited by
- 26
- References
- 3
- FWCI
- 1.66
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dual–Dual Action? Combining Venlafaxine and Mirtazapine in the Treatment of Depression. https://app.cochat.ai/papers/10.1080/00048670701881587
- The paper
- Malhi, G. S., Ng, F., & Berk, M. (2008). Dual–Dual Action? Combining Venlafaxine and Mirtazapine in the Treatment of Depression. Australian & New Zealand Journal of Psychiatry. https://doi.org/10.1080/00048670701881587
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.